Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis

Cancer Prevention Research

Volumn 7, Issue 8, 2014, Pages 835-844

  Hiramoto, Keiichiro ^a,b   Satoh, Hironori ^a   Suzuki, Takafumi ^a   Moriguchi, Takashi ^a   Pi, Jingbo ^c   Shimosegawa, Tooru ^b   Yamamoto, Masayuki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OYL]IMIDAZOLE; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRANSFER RNA; UNCLASSIFIED DRUG; ANTIOXIDANT; IMIDAZOLE; IMIDAZOLE DERIVATIVE; NFE2L2 PROTEIN, MOUSE; TRNA, SELENOCYSTEINE-;

ADHERENT CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER SUSCEPTIBILITY; CARCINOMA CELL; CELL ISOLATION; CELL LINEAGE; CONTROL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENOTYPE; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOREACTIVITY; LEWIS CARCINOMA; LUNG METASTASIS; LUNG WEIGHT; METASTASIS; METASTASIS INHIBITION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERITONEUM MACROPHAGE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUPPRESSOR CELL; TUMOR CELL INOCULATION; UPREGULATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL LINEAGE; GENE DELETION; IMIDAZOLES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, TRANSFER, AMINO ACID-SPECIFIC;

EID: 84905828856     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0094     Document Type: Article

References (50)

1. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-67. (Pubitemid 38263841)
2. Ortega AL, Mena S, Estrela JM. Oxidative and nitrosative stress in the metastatic microenvironment. Cancers 2010;2:274-304.
3. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev 2013;12:376-90.
4. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236:313-22. (Pubitemid 27373291)
5. Ishii T, Itoh K, Takahashi S, Satoh H, Yanagawa T, Katoh Y, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000;275:16023-9. (Pubitemid 30366908)
6. Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, et al. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol Cell Biol 2013;33:2402-12.
7. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemopreventive efficacy of enzyme inducers is lost in nrf2 transcription factordeficient mice. Proc Natl Acad Sci U S A 2001;98:3410-5. (Pubitemid 32220859)
8. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004;64:6424-31. (Pubitemid 39297896)
9. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, et al. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 2007;121:1883-91. (Pubitemid 47463150)
10. Ohkoshi A, Suzuki T, Ono M, Kobayashi T, Yamamoto M. Roles of Keap1-Nrf2 system in upper aerodigestive tract carcinogenesis. Cancer Prev Res 2013;6:149-59.
11. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010;31:1833-43.
12. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-99
13. Kusumartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45. (Pubitemid 41683212)
14. Gabrinovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
15. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86. (Pubitemid 29045117)
16. Taguchi K, Maher JM, Suzuki T, Kawatani Y, Motohashi H, Yamamoto M. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol Cell Biol 2010;30:3016-26.
17. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 2013;34:340-6.
18. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protein against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005;102:4584-9. (Pubitemid 40397155)
19. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, et al. The synthetic triterpenoids, CDDO and CDDO-imidazole, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005;65:4789-98. (Pubitemid 40740817)
20. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemoprevetive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154-62. (Pubitemid 46206678)
21. Deeb D, Gao X, Liu Y, Jiang D, Divine GW, Arbab AS, et al. Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogensis 2011;32:757-64.
22. Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, et al. The synthetic triterpenoid CDDO-Imidazole suppresses experimental liver metastasis. Clin Exp Metastasis 2011;28:309-17.
23. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, Saito E, et al. Selenoprotein P in human plasma as extracellular phospholipid hydroperoxide gluthathione peroxidase. Isolation and enzymatic characterization of human Selenoprotein P. J Biol Chem 1999;274:2866-71. (Pubitemid 29075371)
24. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 2001;21:453-73. (Pubitemid 32695280)
25. Jeong DW, Yoo MH, Kim TS, Kin JH, Kin IY. Protection of mice from allergen-induced asthma by selenite: prevention of eosinophil infiltration by inhibition of NF-kappa B activation. J Biol chem 2002;277:17871-6. (Pubitemid 34967596)
26. Hatfield DL, Gladyshev VN. How selenium has altered our understanding of the genetic code. Mol Cell Biol 2002;22:3565-76. (Pubitemid 34525202)
27. Suzuki T, Kelly VP, Motohashi H, Nakajima O, Takahashi S, Nishijima S, et al. Deletion of the selenocysteine tRNA gene in macrophages and liver results in compensatory gene induction of cytoprotective enzyme by Nrf2. J Biol Chem 2008;283:2021-30.
28. Kawatani Y, Suzuki T, Shimizu R, Kelly VP, Yamamoto M. Nrf2 and selenoproteins are essential for maintaining oxidative homeostasis in erythrocytes and protecting against hemolytic anemia. Blood 2011;117:986-96.
29. Li D, Graef GL, Yee JA, Yan L. Dietary supplementation with high-seleniumsoy protein reduces pulmonary metastasis of melanomacells in mice. J Nutr 2004;134:1536-40. (Pubitemid 38720735)
30. Sato T, Takusagawa K, Asoo N, Kumano N, Hasuike M, Konno K. Conversion of Lewis lung carcinoma into ascetic form. Oncology 1989;46:188-92. (Pubitemid 19117314)
31. Stoner GD, Shimkin MB, Kniazeff AJ, Weisburger JH, Weisburger EK, Gori GB. Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice. Cancer Res 1973;33:3069-85.
32. Xue P, Hou Y, Chen Y, Yang B, FU J, Zheng H, et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 2012;62:845-54.
33. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999;8:265-77. (Pubitemid 29523965)
34. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008;181:4666-75.
35. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007;67:11021-8. (Pubitemid 350145932)
36. Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, Kensler TW, et al. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 2012;53:817-27.
37. Maruyama A, Tsukamoto S, Nishikawa K, Yoshida A, Harada N, Motojima K, et al. Nrf2 regulates the alternative first exons of CD36 in macrophages through specific antioxidant response elements. Arch Biochem Biophys 2008;477:139-45.
38. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 2005;25:8044-51. (Pubitemid 41262998)
39. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-3. (Pubitemid 351556251)
40. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828-35.
41. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-60. (Pubitemid 32691887)
42. Gabrilovich DI, Ostrand-Rosenberg S, Bronte B. Coodinated regulation of myeloid cells by tumors. Nat Rev 2012;12:253-68.
43. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusumartsev S, Sotomayer E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009;182:5693-701.
44. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012;64:972-1003.
45. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011;33:469-76.
46. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008;105:13568-73.
47. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008;135:1358-68.
48. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011;16:123-40.
49. Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, et al. Nrf2 enhances cholangiocyte expansion in pten-deficient livers. Mol Cell Biol 2014;34:900-13.
50. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 2007;46:1597-610. (Pubitemid 350155541)